
The S&P Biotech Index ETF is a popular investment option for those looking to tap into the rapidly growing biotech industry. It's a way to diversify your portfolio and potentially reap the rewards of innovation.
The S&P Biotech Index is comprised of 100 of the largest and most liquid biotech stocks in the US. This index is designed to provide broad exposure to the biotech sector.
Investing in the S&P Biotech Index ETF can be a relatively low-risk way to get involved in the biotech industry. The ETF tracks the S&P Biotech Index, which is calculated by Standard & Poor's.
Intriguing read: 401k S and P Index Only Startegy
Performance and Prices
The S&P Biotech Index ETF has seen some impressive performance numbers over the years. Its current year performance stands at 14.98%.
The ETF's high 1-year performance was 104.11%, indicating a significant increase in value over the past year. However, it's worth noting that the maximum loss in the same period was -20.47%.
A unique perspective: Vanguard Index Funds Returns
The ETF's alpha numbers are a bit concerning, with a 1-year alpha of -13.91% and a 3-year alpha of -15.40%. This suggests that the ETF has underperformed its benchmark over the past few years.
Here are some key performance metrics for the S&P Biotech Index ETF:
The ETF's risk-adjusted returns have been a mixed bag, with a 10-year risk-adjusted return of -8.47% and a 5-year risk-adjusted return of -13.04%. This suggests that the ETF has not provided consistent returns over the long term.
The ETF's tracking error has been relatively high, with a 1-year tracking error of 16.96% and a 5-year tracking error of 21.91%. This means that the ETF's performance has deviated significantly from its benchmark over the past few years.
The ETF's trailing performance has been positive in some periods, with a 1-year trailing return of 6.21% and a 10-year trailing return of 59.04%. However, it's worth noting that the ETF's trailing return has been negative in some periods, such as the 4-year trailing return of -16.04%.
Expand your knowledge: Vanguard S&p 500 Etf Returns
ETF Details
The S&P Biotech Index ETF is an investment option that offers exposure to the biotechnology sector.
This ETF is managed by SPDR, a well-known provider in the ETF space.
The fund tracks the S&P Biotechnology Select Industry Total Return Index - USD, which is a benchmark for the biotech sector.
The expense ratio for this ETF is 0.35%, which is relatively low compared to other investment options.
The fund invests in equities, with no restriction on the size of the companies it invests in.
The currency for this ETF is USD, making it suitable for investors who want to invest in US-based biotech companies.
Here are the key details of the S&P Biotech Index ETF at a glance:
Technical Analysis
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. This suggests a strong buying signal.
The long term indicators fully support a continuation of the trend. This means the trend is likely to persist.
Relative Strength is above 70%, indicating the market is in overbought territory. This means the market may be due for a correction.
Suggestion: Ishares Ibonds Term Tips Etfs
Barchart Technical Opinion
The Barchart Technical Opinion is a valuable tool for traders, and its 100% Buy rating is a strong signal to consider. This rating ranks in the Top 1% of all short term signal directions, indicating a high level of confidence in the trend.
Relative Strength is a key metric that supports the trend, and when it's above 70%, it means the market is in overbought territory. This is a warning sign that a potential trend reversal could be on the horizon.
Long term indicators fully support a continuation of the trend, which is a reassuring sign for traders who are looking to ride the momentum.
Broaden your view: Best Long Term Etfs
Chart: Usd
The USD chart is a crucial tool for technical analysis, helping traders understand the market's trends and patterns.
The USD chart shows a strong correlation with the US 10-year Treasury Yield, which is currently at 1.75%. This indicates a stable economy, but also a potential for inflation.
A rising USD chart often signals a strong economy, which can be a good indicator for investors.
The chart also shows a significant correlation with the US GDP growth rate, which has been steadily increasing over the past year.
A strong USD chart can also lead to a decrease in gold prices, as investors tend to sell their gold holdings when the USD is strong.
Automated Strategies for Xbi
Xbi's automated strategies allow you to create your own algorithmic trading strategy using Composer.
You can leverage Xbi's automated strategies to streamline your trading process and make data-driven decisions.
Create your own algorithmic trading strategy with Xbi using Composer.
Broaden your view: Trading Etfs System
Options Overview Details
Implied volatility has increased by 0.09% to 28.58%, which is a significant change.
The historical volatility of the options is 20.33%, indicating a relatively stable market.
IV Percentile is 62%, which means that the current implied volatility is higher than 62% of the past data.
Check this out: Volatility Index Etf
The IV Rank is 19.85%, which is a measure of how the current implied volatility compares to the past.
The IV High of 56.80% on 04/08/25 was the highest recorded implied volatility in the past.
IV Low of 21.59% on 07/24/25 was the lowest recorded implied volatility in the past.
Here's a breakdown of the current options activity:
Related Topics
If you're interested in biotech ETFs, you might also want to explore the NASDAQ Biotechnology Index, which tracks a similar group of biotech companies.
The NASDAQ Biotechnology Index has a significantly higher concentration of small-cap stocks compared to the S&P Biotech Index ETF.
Biotech ETFs can be a volatile investment, but they also offer the potential for high returns.
The S&P Biotech Index ETF has a minimum market capitalization requirement of $250 million, which helps to filter out smaller, riskier companies.
Investing in biotech ETFs requires a long-term perspective, as the sector can be highly unpredictable in the short term.
Discover more: Nasdaq Etf Index
The S&P Biotech Index ETF has a dividend yield of around 1.5%, which is relatively low compared to other sectors.
Biotech ETFs can be a great way to diversify your portfolio and gain exposure to the biotech industry.
The S&P Biotech Index ETF has a total expense ratio of 0.35%, which is relatively low compared to other ETFs.
For more insights, see: Low Expense Ratio Etfs
Frequently Asked Questions
Is XBI a good buy now?
Based on a strong consensus of 134 buy ratings, XBI is considered a good investment opportunity with a promising 12-month price target of $152.36. However, as with any investment, it's essential to do your own research and consider your individual financial goals before making a decision.
Featured Images: pexels.com


